Clinical Trial Update: Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of Hu3F8, a humanized anti-GD2 antibody, with allogeneic natural killer cells for high-risk neuroblastoma has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Allogeneic natural killer cells
• Hu3F8 (Hu3F8)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroblastoma, High-Risk | Phase 1 | Status: COMPLETED